MRK - weekly breakoutHealthcare has been holding up pretty nice recently lots of names have been strong so this thing looks like it could go to 82 or so
MRK trade ideas
MRK: swing trade!Above 74.80 supports a bullish trend direction. Breaking below this level will negate the bullish stance.
Upside price momentum supports the bullish trend direction.
RSI leaves enough room for further upside price potential.
Trend strength indicates a weak indication that a trend might be developing.
MACD bullish crossover (lower panel) supports a change in trend direction.
A break above its 200-day will act as further support to the trade idea.
Merk & Company USA Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series
Focus: Worldwide
By Sun Storm Investment Research & NexGen Wealth Management Service
A Profit & Solutions Strategy & Research
Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures |
USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India
Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision.
#debadipb #profitsolutions
Merck gaining momentum. MRKImmediate targets 85, 86. Invalidation at 76.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
Price Channel If the pair moving within the price channel breaks the channel, the next target will be the channel width. Investment information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy service is offered individually, taking into account the risk and return preferences of individuals. The content, comments and recommendations contained herein are in no way guiding, but are of a general nature. These recommendations may not be suitable for your financial situation and risk and return preferences. Therefore, making an investment decision based solely on the information contained herein may not yield results that meet your expectations. Burada yer alan yatırım bilgi, yorum ve tavsiyeleri yatırım danışmanlığı kapsamında değildir. Yatırım danışmanlığı hizmeti, bireylerin risk ve getiri tercihleri dikkate alınarak bireysel olarak sunulmaktadır. Burada yer alan içerik, yorum ve tavsiyeler hiçbir şekilde yol gösterici olmayıp genel niteliktedir. Bu öneriler finansal durumunuz ile risk ve getiri tercihlerinize uygun olmayabilir. Bu nedenle, sadece burada yer alan bilgilere dayanarak bir yatırım kararı vermek, beklentilerinizi karşılayan sonuçlar vermeyebilir.
Merck and Co. gearing for a boost. MRKAnd that's expected to an extent after a sizeable and quick drop. Merck did one, and fractally we are due to a rise that can potentially be viable percentage wise. But who knows what will happen.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
MRK - Attempting to retest 3-year range high at 88-90 area Mrk has been making higher lows over the past three years of consolidation between the 70 and 90 range. After finding support at the 200 day MA, the stock could rally toward the range high at the 88 area for a retest. The major resistance is the 92 (year 2000 peak) and 91.4 (Nov 2021 peak).
$MRK breakout...This resolved in the exact way I wanted. Bought 1/21 $80 calls yesterday at $0.26, now almost $1. Now I have plenty of options, 1. Close out take profit and move on, 2. Sell the topside of the spread and have a free trade, 3. Sell the weekly $80's or $80+ spreads and collect premium for 1/7, 1/14 then the topside of the 1/21....
Triple BottomPossible stop under lowest bottom or where you see support.
Possible stop under green dashed line somewhere but keeping in mind market makers do go stop hunting on occasion at the most inopportune times.
Suspicious looking top but a triple bottom can show the bulls made a stand at that level.
Price is at resistance possibly caused from the bottom of previous gap. Another gap or 2 overhead.
The alligator indicator is tangled which can signify consolidation.
No recommendation.
MRK has a lot of headline potential from hereHeadline Potential
Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug:
Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant
Vaxneuvance, a pneumococcal vaccine
Lynparza, a breast cancer drug
Merck also continues to make strong headway with Keytruda, an immunotherapy, which recently picked up another approval in Japan.
All of this means that Merck has a lot of headline potential in coming weeks, especially at a time when a new Covid-19 variant is spreading across the world. There's quite a bit of options activity in Merck today as traders place bets ahead of the news.
Technicals and Sentiment
Merck is currently near support from a long-term trend line and from the 200-day EMA. It has 26% upside to the average analyst price target and a bullish put/call ratio of .43. It has an average analyst rating of 9.3/10, which is very high. It gets an above average ESG score of 2.25/3.
Value
S&P Global gives Merck's fundamentals an average score of 90/100. IIt's currently trading -1.4 standard deviations below where it usually trades in relation to its major moving averages. Forward dividend yield is about 3.7%, forward P/E just over 11, forward P/S about 3.4. The price to free cash flow ratio is fairly high, at over 20, but that has to be interpreted in light of the other multiples. estimate that Merck has about 18% upside to its average price multiple of the last 3 years. Its earnings outlook is highly positive; I score its growth forecast a 5/6.
